Independent risk factors for mortality in patients with chronic obstructive pulmonary disease who undergo comprehensive cardiac evaluations

Respiration

Volumn 90, Issue 3, 2015, Pages 199-205

  Ahn, Young Hwan ^a   Lee, Keu Sung ^a   Park, Joo Hun ^a   Jung, Jin Hee ^a   Lee, Miyeon ^a   Jung, Yun Jung ^a   Chung, Wou Young ^a   Sheen, Seungsoo ^a   Park, Kwang Joo ^a   Kim, Dae Jung ^a   Kang, Dae Ryoung ^a   Lee, Jeong Dong ^a   Yoon, Soojee ^b   Jin, Xiong Jie ^a   Yang, Hyoung Mo ^a   Lim, Hong Seok ^a   Park, Jin Sun ^a   Shin, Joon Han ^a   Tahk, Seung Jea ^a  

^a Ajou University School of Medicine   (South Korea)

^b Wooridul Hospital   (South Korea)

Author keywords

Chronic obstructive pulmonary disease; Hemoglobin levels; Left heart failure; Mortality

Indexed keywords

HEMOGLOBIN;

AGED; ANEMIA; ANGIOCARDIOGRAPHY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; SURVIVAL TIME; ANALYSIS OF VARIANCE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT ANALYSIS; CORONARY ANGIOGRAPHY; DOPPLER ECHOCARDIOGRAPHY; INCIDENCE; KAPLAN MEIER METHOD; LUNG FUNCTION TEST; MIDDLE AGED; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; SURVIVAL ANALYSIS; UNIVERSITY HOSPITAL;

AGED; ANALYSIS OF VARIANCE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; CORONARY ANGIOGRAPHY; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPUBLIC OF KOREA; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84954363886     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000437097     Document Type: Article

References (32)

1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
2. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ: Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
3. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, Van Empel VP, Bruijnzeel PL, Rutten EP, Op t Roodt J, Wouters EF, Franssen FM: Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728-735.
4. McAllister DA, Maclay JD, Mills NL, Mair G, Miller J, Anderson D, Newby DE, Murchison JT, Macnee W: Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 1208-1214.
5. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH Investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
6. Preiss D, Thomas LE, Sun JL, Haffner SM, Holman RR, Standl E, Leiter LA, Mazzone T, Rutten GE, Tognoni G, Martinez FA, Chiang FT, Califf RM, McMurray JJ: Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open 2012; 2: pii: e001925.
7. Le Jemtel TH, Padeletti M, Jelic S: Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiology 2007; 49: 171-180.
8. De Miguel Diez J, Chancafe Morgan J, Jimenez Garcia R: The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis 2013; 8: 305-312.
9. Reed RM, Eberlein M, Girgis RE, Hashmi S, Iacono A, Jones S, Netzer G, Scharf S: Coronary artery disease is under-diagnosed and undertreated in advanced lung disease. Am J Med 2012; 125: 1228.e13-1228.e22.
10. Brekke PH, Omland T, Smith P, Soyseth V: Underdiagnosis of myocardial infarction in COPD- Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med 2008; 102: 1243-1247.
11. Williams MC, Murchison JT, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo J, Wouters E, Yates JC, Van Beek EJ, Newby DE, MacNee W; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators: Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax 2014; 69: 718-723.
12. Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD: COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068-2075.
13. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP: Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-269.
14. Beutler E, Waalen J: The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?. Blood 2006; 107: 1747-1750.
15. Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC; COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group: Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60: 480-487.
16. Oh YM, Sheen SS, Park JH, Jin UR, Yoo JW, Seo JB, Yoo KH, Lee JH, Kim TH, Lim SY, Yoon HI, Lee JS, Lee SD: Emphysematous phenotype is an independent predictor for frequent exacerbation of COPD. Int J Tuberc Lung Dis 2014; 18: 1407-1414.
17. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
18. Lewis S, Clarke M: Forest plots: trying to see the wood and the trees. BMJ 2001; 322: 1479-1480.
19. Berger JS, Sanborn TA, Sherman W, Brown DL: Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol 2004; 94: 649-651.
20. Sin DD, Man SF: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases?. The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
21. Slenter RH1, Sprooten RT, Kotz D, Wesseling G, Wouters EF, Rohde GG: Predictors of 1-year mortality at hospital admission for acute exacerbations of chronic obstructive pulmonary disease. Respiration 2013; 85: 15-26.
22. Sin DD, Wu L, Man SF: The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127: 1952-1959.
23. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, Jiang R, Kawut SM, Kronmal RA, Lima JA, Shahar E, Smith LJ, Watson KE: Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362: 217-227.
24. Chambellan A, Chailleux E, Similowski T: Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest 2005; 128: 1201-1208.
25. Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B: Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007; 29: 923-929.
26. Silverberg DS, Mor R, Weu MT, Schwartz D, Schwartz IF, Chernin G: Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med 2014; 14: 24.
27. Celli BR, Cote CG, Marin JM, Casanova C, Montes De Oca M, Mendez RA, Pinto Plata V, Cabral HJ: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
28. Schonhofer B, Wenzel M, Geibel M, Kohler D: Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med 1998; 26: 1824-1828.
29. Boutou AK, Karrar S, Hopkinson NS, Polkey MI: Anemia of chronic disease in chronic obstructive pulmonary disease: a case-control study of cardiopulmonary exercise responses. Respiration 2013; 85: 126-131.
30. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG: Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 982-988.
31. Ross R: Atherosclerosis - An inflammatory disease. N Engl J Med 1999; 340: 115-126.
32. John M, Hoernig S, Doehner W, Okonko DD, Witt C, Anker SD: Anemia and inflammation in COPD. Chest 2005; 127: 825-829.